摘要
目的:观察骨髓增生异常综合征(MDS)患者中Livin基因水平的表达,探讨Livin基因在MDS中的可能临床意义。方法:收集确诊为MDS(诊断和分型参照WHO标准)患者共30例,对照组共10例。采用实时荧光定量PCR方法检测Livin mRNA水平(△Ct值越小,表明目的基因的表达量越大);Western Blotting方法检测Livin蛋白水平。结果:①MDS组Livin mRNA水平△Ct均值为(15.44±4.50),对照组Livin mRNA水平△Ct值为(20.91±0.53),2组比较差异有统计学意义(P<0.01);MDS组Livin蛋白相对表达量为(0.556 6±0.229 3),对照组Livin蛋白相对表达量为(0.201 2±0.010 7),2组比较差异有统计学意义(P<0.01)。②MDS组内低危、中危、高危患者的Livin mRNA水平△Ct值分别为(19.16±3.88)、(16.38±4.36)、(13.35±3.71),3组两两比较差异有统计学意义(P<0.01),高危患者Livin mRNA表达水平最高,中危患者其次,低危患者最低;MDS组内低危、中危、高危患者的Livin蛋白表达分别为(0.234 2±0.039 4)、(0.472 5±0.079 1)、(0.751 8±0.091 0),3组两两比较差异有统计学意义(P<0.01),高危患者Livin蛋白表达水平最高,中危患者其次,低危患者最低。结论:MDS患者的Livin mRNA和蛋白的表达水平均较对照组表达增高,MDS患者低危、中危和高危组中Livin mRNA和蛋白的表达水平依次升高。Livin基因表达可能与MDS疾病相关,同时表达水平的高低可能与疾病的危险分层相关。
Objective:To investigate the expression and clinical implication of Livin gene in patients with myelodysplastic syndrome(MDS).Method:Thirty patients with MDS were enrolled according to diagnosis criteria of the WHO classification,and 10 persons were recruited as control group.The expression of Livin gene was detected by real time quantitative PCR at mRNA level,by Western Blotting at protein level respectively.Result:①The expression of Livin gene was higher in the MDS group compared that in the control group.The value of△Ct in MDS was(15.44±4.50),which was significantly lower than the value of(20.91±0.53)in the control group(P〈0.01).The protein expression of Livin gene in MDS group was significantly higher than that of control group[(0.556 6±0.229 3)vs.(0.201 2±0.010 7),P〈0.01].②The △Ct in low-risk,intermediate-risk and high-risk MDS patients were(19.16±3.88),(16.38±4.36),and(13.35±3.71)respectively.The protein expression in low-risk,intermediate-risk and high-risk MDS patients were(0.234 2±0.039 4),(0.472 5±0.079 1),(0.751 8±0.091 0)respectively.Conclusion:The expressions of Livin mRNA and protein are significantly higher in MDS patients than those in control group,which indicates the involvement of Livin in MDS.The expression of Livin is probably correlated with risk of MDS.
作者
周文锦
郑翠苹
石岳坚
胡映映
ZHOUWenjin ZHENG Cuiping SHI Yuejian HUYingying(Department of Hematology, Wenzhou Central Hospital, Wenzhou, a25ooo, Chin)
出处
《临床血液学杂志》
CAS
2016年第5期730-733,共4页
Journal of Clinical Hematology
基金
温州市科技计划项目(No:Y20140293)